Erratum: Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence

Authors

  • Stefan Faderl MD,

  • Alessandra Ferrajoli MD,

  • William Wierda MD, PhD,

  • Susan O'Brien MD,

  • Susan Lerner MD,

  • Michael J. Keating MD

Errata

This article corrects:

  1. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence Volume 116, Issue 10, 2360–2365, Article first published online: 11 March 2010

A dose was presented incorrectly in this article. The statement on page 2 should have read as follows.

Alemtuzumab was initiated as a civ over 24 hours at a dose of 15 mg/day for a total of 6 days (Days 2 to 7) followed by 30 mg sc twice a week on Days 3 and 5 of Weeks 2 to 4.

The authors regret this error.

Ancillary